n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide and Hematologic Diseases

n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide has been researched along with Hematologic Diseases in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beijnen, JH; Copalu, W; Huitema, AD; Schellens, JH; Zandvliet, AS	1
Armand, JP; Beijnen, JH; Faivre, S; Fumoleau, P; Ravic, M; Raymond, E; Schellens, JH; Taïeb, J; ten Bokkel Huinink, WW; Wanders, J	1
Droz, JP; Faber, MN; Ravic, M; Roché, H; Schellens, JH; Terret, C; Wanders, J; Zanetta, S	1

Trials

2 trial(s) available for n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide and Hematologic Diseases

Article	Year
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Aug-15, Volume: 20, Issue:16 Topics: Adult; Aged; Antineoplastic Agents; Drug Eruptions; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms; Sulfonamides	2002
Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:8 Topics: Adult; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Fatigue; Female; Hematologic Diseases; Humans; Hypokalemia; Infusions, Intravenous; Kidney Diseases; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Platelet Count; Sulfonamides; Vomiting	2003

Article

Year

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Aug-15, Volume: 20, Issue:16

Topics: Adult; Aged; Antineoplastic Agents; Drug Eruptions; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms; Sulfonamides

2002

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).

European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:8

Topics: Adult; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Fatigue; Female; Hematologic Diseases; Humans; Hypokalemia; Infusions, Intravenous; Kidney Diseases; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Platelet Count; Sulfonamides; Vomiting

2003

Other Studies

1 other study(ies) available for n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide and Hematologic Diseases

Article	Year
Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. Journal of pharmacokinetics and pharmacodynamics, 2009, Volume: 36, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Body Surface Area; Clinical Trials as Topic; Computer Simulation; Cytochrome P-450 Enzyme System; Cytotoxins; Female; Hematologic Diseases; Humans; Male; Middle Aged; Models, Biological; Models, Statistical; Neutropenia; Racial Groups; Risk; Risk Factors; Sex Factors; Sulfonamides; Thrombocytopenia; Young Adult	2009

Article

Year

Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.

Journal of pharmacokinetics and pharmacodynamics, 2009, Volume: 36, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Body Surface Area; Clinical Trials as Topic; Computer Simulation; Cytochrome P-450 Enzyme System; Cytotoxins; Female; Hematologic Diseases; Humans; Male; Middle Aged; Models, Biological; Models, Statistical; Neutropenia; Racial Groups; Risk; Risk Factors; Sex Factors; Sulfonamides; Thrombocytopenia; Young Adult

2009